Important Update for LifeMD, Inc. Investors
LifeMD, Inc. (NASDAQ: LFMD) has come under scrutiny as a class action lawsuit has been initiated against the company. This important legal development arises from allegations that LifeMD made materially false and misleading statements regarding its business practices and financial outlook.
About LifeMD, Inc.
Headquartered in New York, LifeMD is a prominent telehealth provider. The company specializes in offering direct-to-patient virtual care and pharmacy services, aiming to revolutionize how healthcare is delivered. Their innovative approach allows patients to access medical services from the comfort of their homes.
Background of the Lawsuit
The class action lawsuit, which is being spearheaded by national plaintiffs' law firm Berger Montague, is on behalf of investors who acquired shares during a specific class period. This period is defined as commencing on May 7, 2025, through August 5, 2025. The lawsuit claims that the company inflated its competitive standing and set unrealistic financial guidance while failing to acknowledge the rising customer acquisition costs, especially in the RexMD segment and the market for obesity-related treatments.
Impact on Investors
Upon the revelation of these facts, LifeMD's stock saw a significant decrease, plummeting by 44% or $5.31 per share in a single trading session. This sharp decline has caused concern among current investors regarding their investments and the viability of the company’s reported financial health.
Taking Action
Investors who participated in trading LifeMD shares during the class period are encouraged to understand their rights. Those interested in potentially acting as lead plaintiffs in the class may seek to initiate this process by the deadline of October 27, 2025. It is crucial for affected investors to seek legal advice as soon as possible to navigate this situation effectively.
About Berger Montague
Berger Montague is a well-established name in the realm of securities class action litigation, having operated since 1970. With offices across multiple cities, the firm has garnered a reputation for representing both individual and institutional investors. They strive to ensure that justice is served and that the interests of investors are diligently protected.
Contact Information
For more information or to explore your options in this ongoing legal matter, you are invited to reach out to the following contacts at Berger Montague:
Andrew Abramowitz
Senior Counsel
(215) 875-3015
Email: [email protected]
Caitlin Adorni
Director of Portfolio and Institutional Client Monitoring Services
(267) 764-4865
Email: [email protected]
Frequently Asked Questions
What is the lawsuit against LifeMD about?
The lawsuit accuses LifeMD of making misleading statements about its business and financial position, leading to significant investor losses.
Who can participate in the class action?
Investors who purchased LifeMD shares during the class period from May 7, 2025, to August 5, 2025, may participate.
What are the potential outcomes of the class action?
Possible outcomes include financial compensation for affected investors if the lawsuit is successful in proving the claims.
What should investors do if they believe they are affected?
Affected investors should seek legal counsel to understand their rights and consider engaging in the class action process.
What is the deadline for investors to take action?
Investors should act by October 27, 2025, to ensure they can potentially serve as lead plaintiffs in the case.
